Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that it will report 2018 fourth quarter and full year financial results after market close on Tuesday, February 26, 2019....
Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company, announces that Nestle Health Science has exercised its option to obtain an exclusive license for the global development and commercialization...
Codexis, Inc. (NASDAQ: CDXS) announces a multi-year, exclusive supply agreement with KYORIN Pharmaceutical Co., Ltd. for the supply of a proprietary enzyme to be used in the manufacture of vibegron, an...
Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces the signing of a new agreement with Merck, through a subsidiary. Under the terms of the agreement, Codexis will install certain...
Codexis (CDXS) delivered earnings and revenue surprises of 100.00% and 15.81%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
REDWOOD CITY, Calif. (AP) _ Codexis Inc. (CDXS) on Thursday reported a loss of $2 million in its third quarter.
Total revenues increase 70% to $16.9 million driven by higher product revenue and R&D revenue across an increased number of customers
CDX-6114 meets safety and tolerability endpoints
Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that management will present at two upcoming investment conferences:
Codexis (CDXS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Arsanis, Inc. (NASDAQ:ASNS),...
Cimpress' (CMPR) management has decentralized operations to improve accountability for customer satisfaction and capital returns, simplify decision-making and improve the speed of execution.
Sonoco's (SON) prospects remain bright on the back of solid earnings estimate revision activity as well as an upbeat guidance.
REDWOOD CITY, Calif. (AP) _ Codexis Inc. (CDXS) on Thursday reported a loss of $4.7 million in its first quarter.
Total revenues increase 76% to $14.0 million on sharply higher R&D revenue
Codexis, Inc. (NASDAQ: CDXS) and Porton Pharma Solutions, Ltd. (SZSE: 300363) announce a strategic collaboration to deploy Codexis' world-leading biocatalyst technology within...
EnzymeWorks has been ordered by the United States District Court for the Northern District of California to retract its prior statements and press releases pertaining in any way to the settlement...
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Alliance Resource Partners,...
Codexis, Inc. (Nasdaq:CDXS), a leading protein engineering company, today announced the pricing of an underwritten public offering of 3,750,000 shares of its common stock at a public offering price of...
Codexis, Inc. (Nasdaq:CDXS), a leading protein engineering company, today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares to be sold in...
